EP1221941A4 - Powder pharmaceutical formulations - Google Patents

Powder pharmaceutical formulations

Info

Publication number
EP1221941A4
EP1221941A4 EP00982684A EP00982684A EP1221941A4 EP 1221941 A4 EP1221941 A4 EP 1221941A4 EP 00982684 A EP00982684 A EP 00982684A EP 00982684 A EP00982684 A EP 00982684A EP 1221941 A4 EP1221941 A4 EP 1221941A4
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical formulations
powder pharmaceutical
powder
formulations
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00982684A
Other languages
German (de)
French (fr)
Other versions
EP1221941A1 (en
Inventor
Ronald L Ream
William J Wokas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
WM Wrigley Jr Co
Original Assignee
WM Wrigley Jr Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by WM Wrigley Jr Co filed Critical WM Wrigley Jr Co
Publication of EP1221941A1 publication Critical patent/EP1221941A1/en
Publication of EP1221941A4 publication Critical patent/EP1221941A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP00982684A 1999-10-20 2000-10-18 Powder pharmaceutical formulations Withdrawn EP1221941A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42190599A 1999-10-20 1999-10-20
US421905 1999-10-20
PCT/US2000/041225 WO2001028523A1 (en) 1999-10-20 2000-10-18 Powder pharmaceutical formulations

Publications (2)

Publication Number Publication Date
EP1221941A1 EP1221941A1 (en) 2002-07-17
EP1221941A4 true EP1221941A4 (en) 2005-11-30

Family

ID=23672581

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00982684A Withdrawn EP1221941A4 (en) 1999-10-20 2000-10-18 Powder pharmaceutical formulations

Country Status (6)

Country Link
EP (1) EP1221941A4 (en)
JP (1) JP2003512315A (en)
CN (1) CN1374859A (en)
AU (1) AU779170B2 (en)
CA (1) CA2382978A1 (en)
WO (1) WO2001028523A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4373649B2 (en) * 2002-08-01 2009-11-25 ロート製薬株式会社 Oral solution
SE0500006L (en) * 2005-01-04 2006-07-05 Peter Stigsson Device for ingesting caffeine in an oral cavity
DE102005040463A1 (en) * 2005-08-26 2007-03-01 Cognis Ip Management Gmbh Use of mixtures of polyphenols and physiologically active unsaturated fatty substances
JP5620040B2 (en) * 2007-01-19 2014-11-05 エスエス製薬株式会社 Oral composition
CN103005367A (en) * 2012-12-17 2013-04-03 楚大波 Bitterness screening agent as well as preparation method and application thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3433872A (en) * 1966-11-25 1969-03-18 Hoffmann La Roche Palatable,free-flowing,non-agglomerating caffeine powder
US4647450A (en) * 1983-07-20 1987-03-03 Warner-Lambert Company Chewing gum compositions containing magnesium trisilicate absorbates
US5456677A (en) * 1994-08-22 1995-10-10 Spector; John E. Method for oral spray administration of caffeine
WO1998023165A1 (en) * 1996-11-27 1998-06-04 Wm. Wrigley Jr. Company Method of controlling release of caffeine in chewing gum and gum produced thereby
US5785984A (en) * 1993-02-05 1998-07-28 Kao Corporation Taste-modifying method and bitterness-decreasing method
WO2000059543A1 (en) * 1999-04-06 2000-10-12 Wm. Wrigley Jr. Company Over-coated chewing gum formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262179A (en) * 1989-09-13 1993-11-16 Nicholas Kiwi Pty Ltd. Non-effervescent ibuprofen compositions
US5032411A (en) * 1990-02-27 1991-07-16 University Of Texas System Board Of Regents Beverage compositions for human consumption
US5631038A (en) * 1990-06-01 1997-05-20 Bioresearch, Inc. Specific eatable taste modifiers
US5607697A (en) * 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
JPH10298086A (en) * 1997-04-30 1998-11-10 Taisho Pharmaceut Co Ltd Oral composition
US5869098A (en) * 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3433872A (en) * 1966-11-25 1969-03-18 Hoffmann La Roche Palatable,free-flowing,non-agglomerating caffeine powder
US4647450A (en) * 1983-07-20 1987-03-03 Warner-Lambert Company Chewing gum compositions containing magnesium trisilicate absorbates
US5785984A (en) * 1993-02-05 1998-07-28 Kao Corporation Taste-modifying method and bitterness-decreasing method
US5456677A (en) * 1994-08-22 1995-10-10 Spector; John E. Method for oral spray administration of caffeine
WO1998023165A1 (en) * 1996-11-27 1998-06-04 Wm. Wrigley Jr. Company Method of controlling release of caffeine in chewing gum and gum produced thereby
WO2000059543A1 (en) * 1999-04-06 2000-10-12 Wm. Wrigley Jr. Company Over-coated chewing gum formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0128523A1 *

Also Published As

Publication number Publication date
CA2382978A1 (en) 2001-04-26
WO2001028523A1 (en) 2001-04-26
CN1374859A (en) 2002-10-16
EP1221941A1 (en) 2002-07-17
JP2003512315A (en) 2003-04-02
AU779170B2 (en) 2005-01-13
AU1968201A (en) 2001-04-30

Similar Documents

Publication Publication Date Title
HUP0202513A3 (en) Betha-carboline pharmaceutical compositions
HUP0202235A3 (en) Preserved pharmaceutical formulations
GB0028088D0 (en) Pharmaceutical compositions
GB0001662D0 (en) Pharmaceutical compositions
HK1044476A1 (en) Medicinal compositions
GB9923436D0 (en) Pharmaceutical compositions
HK1045804A1 (en) Improved pharmaceutical formulations comprising ritonavir
EP1166786A4 (en) Medicinal compositions
GB9904163D0 (en) Pharmaceutical compositions
HK1046140A1 (en) Solid pharmaceutical preparation
GB9911017D0 (en) Pharmaceutical compositions
HK1045102A1 (en) Pharmaceutical formulations
GB9924992D0 (en) Pharmaceutical aerosol formulations
EP1221941A4 (en) Powder pharmaceutical formulations
GB9909154D0 (en) Pharmaceutical formulation
GB9904911D0 (en) Pharmaceutical compositions
GB9930578D0 (en) Pharmaceutical formulations
GB9906126D0 (en) Pharmaceutical formulations
GB9926251D0 (en) Pharmaceutical formulation
GB9902651D0 (en) Pharmaceutical compositions
GB9911826D0 (en) Pharmaceutical formulations
GB9905983D0 (en) Pharmaceutical formulations
GB9903177D0 (en) Pharmaceutical formulations
GB9917777D0 (en) Pharmaceutical formulation
GB9921396D0 (en) Pharmaceutical formulation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020326

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20051012

17Q First examination report despatched

Effective date: 20060717

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080312